More than half of neurology fellows experience burnout

A recent study, published in Neurology, found more than half of neurology fellows experience at least one symptom of burnout.

Led by Kerry H. Levin, MD, FAAN, chair of neurology at the Cleveland Clinic and chair of the American Academy of Neurology (AAN) Resident Burnout Subcommittee, the study aimed at outlining rates of burnout in U.S. residents and fellows. Researchers hope these results could help create current practices to combat burnout.

The study enrolled 938 members of the U.S. AAN working as residents and fellows. With a 37.7 percent response rate, 354 participants were surveyed on measures of burnout, career satisfaction and well-being from January to March 2016.

Overall, two thirds of participants were residents and a third were fellows. Results showed that 73 percent of residents and 55 percent of fellows experienced at least one symptom of burnout, mostly related to the higher scores of depersonalization in residents. Improved rates of work-life balance, meaningful work and older age correlated with lower rates of burnout in residents. Fellows experienced lower rates of burnout with greater satisfaction with work-life balance and support staff. Those experiencing burnout were less likely to be satisfied with their careers.

“Burnout is common in neurology residents and fellows. Lack of work–life balance and lack of meaning in work were associated with reduced career satisfaction and increased risk of burnout,” concluded Levin and colleagues. “These results should inform approaches to reduce burnout and promote career satisfaction and well-being in U.S. neurology trainees.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.